Application of Cephaloziellin F in preparation of drugs for treating chronic granulocytic leukemia

A chronic myeloid leukemia technology, applied in drug combination, antineoplastic drugs, pharmaceutical formulations, etc., can solve the problem that there is no report of chronic myeloid leukemia activity

Inactive Publication Date: 2016-02-17
吴正锋
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] There is no report on the activity of this compound in the treatment of chronic myelogenous leukemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Cephaloziellin F in preparation of drugs for treating chronic granulocytic leukemia
  • Application of Cephaloziellin F in preparation of drugs for treating chronic granulocytic leukemia
  • Application of Cephaloziellin F in preparation of drugs for treating chronic granulocytic leukemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0010] Example 1: Isolation, Preparation and Structure Confirmation of Cephaloziellin F

[0011] The preparation method of Cephaloziellin F is the same as that reported in the literature (Secondary Metabolites from the Chinese Liverwort Cephaloziellakiaeri, J. Nat. Prod., 2013, 76, 1700-1708).

[0012] Confirmation of structure: colorless oil (methanol). According to HR-ESI-MS, the molecular formula is C 21 h 26 o 6 , with an unsaturation of 9. H NMR spectrum data δ H (ppm, DMSO-d 6 , 600MHz): H-1(1.49, m), H-1(1.91, m), H-2(2.32, m), H-2(2.11, m), H-3(6.83, br, s) , H-6 (1.79, m), H-6 (2.13, m), H-7 (2.83, m), H-7 (2.22, m), H-9 (2.95, t, J=9.6), H-10 (1.53, m), H-11 (2.35, m, 2H), H-12 (5.40, br, d, J=6.6), H-14 (6.29, br, s), H-15 ( 7.35, br, s), H-16 (7.37, br, s), H-17 (2.04, s), H-19 (1.11, s), 18-OMe (3.70, s); carbon NMR data δ C (ppm, DMSO-d 6 , 150Hz): 20.8 (CH 2 , 1-C), 25.7 (CH 2 , 2-C), 139.1 (CH, 3-C), 136.2 (C, 4-C), 39.0 (C, 5-C), 29.4 (CH 2 , 6-C...

Embodiment 2

[0013] Embodiment 2: Pharmacological action test of Cephaloziellin F

[0014] 1. Materials and Instruments

[0015] K562 cells were provided by Shanghai Institute of Biological Cells, Chinese Academy of Sciences. Cephaloziellin F is self-made, and the HPLC normalized purity is greater than 98%. RPMI-1640 dry powder medium was purchased from Gibco. Calf serum was purchased from Hangzhou Sijiqing Institute of Bioengineering Materials. Penicillin and streptomycin were purchased from Huabei Pharmaceutical Factory. Glutamine, MTT, DMSO were purchased from AMRESCO. Annexinv-FITC cell apoptosis detection kit was purchased from Nanjing KGI Biotechnology Development Co., Ltd. MOPS, Rnasin, agarose, olfactory ethidium, bromophenol blue Huamei Bioengineering Company Huamei Bioengineering Company.

[0016] CO 2 Incubator (Thermo Company, USA), ultra-clean bench (Suzhou Purification Equipment Factory), magnetic stirrer (Shanghai Nanhui Telecommunication Equipment Factory), inverted ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
degree of unsaturationaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of Cephaloziellin F in preparation of drugs for treating chronic granulocytic leukemia, and belongs to the field of drugs. According to research, the Cephaloziellin F can directly inhibit proliferation of K562 cells, and inhibiting ability is improved along with increasing of concentration and extension of action time. Moreover, the Cephaloziellin F can induce K562 cell apoptosis, and the apoptosis promoting effect can be improved along with increasing of the concentration and extension of the time. Therefore, the Cephaloziellin F can be further researched and developed into the drugs for treating the chronic granulocytic leukemia.

Description

technical field [0001] The present invention relates to a new application of compound Cephaloziellin F, in particular to the application of Cephaloziellin F in the preparation of medicaments for treating chronic myeloid leukemia. Background technique [0002] Rui-JuanLi et al. isolated and purified the compound Cephaloziellin F for the first time, and published the results in the famous Journal of Natural Products (Secondary Metabolites from the Chinese Liverwort Cephaloziellakiaeri, J. Nat. Prod., 2013, 76, 1700-1708). [0003] At present, there is no report on the activity of this compound in the treatment of chronic myelogenous leukemia. Contents of the invention [0004] The purpose of the present invention is to provide a medical application of Cephaloziellin F. [0005] The above-mentioned purpose is achieved through the following technical solutions: [0006] Application of CephaloziellinF in the preparation of a medicine for treating chronic myeloid leukemia, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P35/02
CPCA61K31/365
Inventor 吴正锋
Owner 吴正锋
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap